Savolitinib (AZD6094) demonstrated the ability to overcome MET resistance in patients with EGFR-mutant, MET-amplified or -overexpressed non–small cell lung cancer (NSCLC) when combined with osimertinib (Tagrisso), and these benefits extended to those with disease that had previously progressed on a prior EGFR tyrosine kinase inhibitor (TKI). These results from the final analysis of the expansion cohorts of the phase 1b TATTON study (NCT02143466) were presented virtually at the 2020 World Conference on Lung Cancer Singapore.1
In part B of the trial, which had 3 cohorts, results showed that the overall response rate (ORR) was 33% (95% CI, 22%-46%) in cohort 1, in which patients had received a prior third-generation EGFR TKI. Cohort 2, in which patients did not have a prior third-generation EGFR TKI and were T790M-negative, showed an ORR of 65% (95% CI, 50%-78%).
In cohort 3, where…
